Clinical Research Directory
Browse clinical research sites, groups, and studies.
JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
Sponsor: Jacobio Pharmaceuticals Co., Ltd.
Summary
This study is to evaluate the efficacy and safety of JAB-30355 in adult participants with advanced solid tumors harboring TP53 Y220C mutation.
Official title: A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-30355 in Adult Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
144
Start Date
2024-07-24
Completion Date
2027-07
Last Updated
2026-01-22
Healthy Volunteers
No
Conditions
Interventions
JAB-30355
Oral administration
JAB-30355
Oral administration
Locations (13)
Research Site
Denver, Colorado, United States
Research site
Lake Mary, Florida, United States
Research site
St Louis, Missouri, United States
Research site
Canton, Ohio, United States
Research site
Cleveland, Ohio, United States
Research Site
Nashville, Tennessee, United States
Research site
Houston, Texas, United States
Research Site
Beijing, Beijing Municipality, China
Research Site
Beijing, Beijing Municipality, China
Research Site
Beijing, Beijing Municipality, China
Research Site
Guangzhou, Guangdong, China
Research Site
Jinan, Shandong, China
Research Site
Shanghai, Shanghai Municipality, China